PFE Stock Recent News

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Viking Therapeutics may appeal to risk-tolerant growth investors.

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosulif, Padcev, Oxbryta, and Abrysvo, the company's dividend yield exceeds 6.5%. So, sales of Abrysvo amounted to $515 million in the fourth quarter of 2023, an increase of 37.3% compared to the previous quarter.

Pfizer's stock has been a disappointment in recent times due to a number of factors. This includes a decline in Covid cases as well as looming patent protection expirations.

PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GILD in its post-HCV stagnation.

Pfizer (PFE) closed the most recent trading day at $25.91, moving +0.19% from the previous trading session.

Pfizer has been struggling since its coronavirus vaccine sales started to fall. It's making a big move into cancer drugs, which should help it diversify.

Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ambitious plans to launch new products and indications, which could drive significant revenue growth. Pfizer's investment in oncology and the use of AI in drug development are promising, and the company's valuation suggests upside potential.

Pfizer's PEG ratio according to one widely used financial website is shockingly low. This low valuation metric raises questions.